🇺🇸 FDA
Patent

US 8877725

Peptide conjugated, inosine-substituted antisense oligomer compound and method

granted A61KA61K48/0008A61P

Quick answer

US patent 8877725 (Peptide conjugated, inosine-substituted antisense oligomer compound and method) held by Sarepta Therapeutics, Inc. expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K48/0008, A61P, A61P13/12, A61P31/12